[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Bhavdip Sanghavi [@bhavdip143](/creator/twitter/bhavdip143) on x 19K followers Created: 2025-07-10 03:16:55 UTC $IBX $IBX surged XX% today, but this is just the beginning. Imagion Biosystems (ASX: IBX) has achieved a significant milestone with positive feedback from the FDA on its Phase X HER2 breast cancer trial. This progress underscores the potential of their MagSense® technology in revolutionizing cancer detection. Key Highlights: FDA Engagement: Received constructive feedback on the study plan and outcomes, paving the way for the upcoming IND submission. Manufacturing Progress: Initiated production of the MagSense® HER2 Imaging Agent, adhering to FDA's Good Manufacturing Practices (GMP). Phase X Objectives: Aiming to optimize dosing and imaging protocols to enhance diagnostic performance in detecting axillary nodal disease in HER2-positive breast cancer patients. Technological Advantage: MagSense® offers a non-radioactive, molecularly targeted imaging solution, potentially reducing the need for invasive biopsies. With over XXXXXXX HER2-positive breast cancer cases diagnosed annually worldwide, the clinical need for precise imaging is immense. The momentum behind $IBX is building, and this could be a transformative period for the company. DYOR. Not financial advice. XXXXX engagements  **Related Topics** [$atx](/topic/$atx) [tide](/topic/tide) [stocks technology](/topic/stocks-technology) [$ibx](/topic/$ibx) [Post Link](https://x.com/bhavdip143/status/1943147393970573717)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Bhavdip Sanghavi @bhavdip143 on x 19K followers
Created: 2025-07-10 03:16:55 UTC
$IBX
$IBX surged XX% today, but this is just the beginning.
Imagion Biosystems (ASX: IBX) has achieved a significant milestone with positive feedback from the FDA on its Phase X HER2 breast cancer trial. This progress underscores the potential of their MagSense® technology in revolutionizing cancer detection.
Key Highlights:
FDA Engagement: Received constructive feedback on the study plan and outcomes, paving the way for the upcoming IND submission.
Manufacturing Progress: Initiated production of the MagSense® HER2 Imaging Agent, adhering to FDA's Good Manufacturing Practices (GMP).
Phase X Objectives: Aiming to optimize dosing and imaging protocols to enhance diagnostic performance in detecting axillary nodal disease in HER2-positive breast cancer patients.
Technological Advantage: MagSense® offers a non-radioactive, molecularly targeted imaging solution, potentially reducing the need for invasive biopsies.
With over XXXXXXX HER2-positive breast cancer cases diagnosed annually worldwide, the clinical need for precise imaging is immense.
The momentum behind $IBX is building, and this could be a transformative period for the company.
DYOR. Not financial advice.
XXXXX engagements
Related Topics $atx tide stocks technology $ibx